Skip to main content
Tego Science, Inc. logo

Tego Science, Inc. — Investor Relations & Filings

Ticker · 191420 ISIN · KR7191420009 KO Manufacturing
Open in API
Filings indexed 155 across all filing types
Latest filing 2026-05-19 M&A Activity
Country KR South Korea
Listing KO 191420

About Tego Science, Inc.

http://www.tegoscience.com/

Tego Science, Inc. is a biopharmaceutical company specializing in the development and commercialization of cell therapies for regenerative medicine. The company leverages proprietary, advanced cell culture technology for the mass production of human epithelial cells. Its portfolio of approved products includes Holoderm®, an autologous cultured epidermis for severe burns; Kaloderm®, an allogeneic cell therapy for burns and diabetic foot ulcers; and Rosmir®, an autologous fibroblast treatment for wrinkles. In addition to its therapeutic products, Tego Science provides Neoderm®, a 3D cultured skin model used as an alternative to animal testing, and offers CDMO services. The company's clinical pipeline features TPX-115, a first-in-class allogeneic fibroblast-based therapy for treating rotator cuff tears, currently in late-stage clinical trials.

Recent filings

Filing Released Lang Actions
타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 82% confidence The document is a voluntary disclosure (“자율공시”) detailing the company’s decision to acquire shares and equity securities of another corporation (95.77% stake), with full acquisition terms, amounts, dates and rationale. This is not a share issuance or repurchase of its own stock, nor a fundraising announcement; it is a strategic acquisition/takeover. According to our definitions, this falls under M&A Activity (Code: TAR).
2026-05-19 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서” (quarterly report) for the period January 1 to March 31, 2026 (1st quarter), includes detailed financial statements, business overview, capital changes, production data, sales data, and risk management. It is a substantive interim/quarterly financial report rather than an announcement or certification, matching the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled “정기주주총회결과” and provides detailed voting outcomes for each resolution at the Annual General Meeting, including approval of financial statements, amendments, director appointments, and vote percentages. This matches a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Tego Science. It provides the auditor's opinion (unqualified/appropriate), financial highlights (assets, liabilities, equity, profit/loss), and details regarding the audit process. While it contains financial data, it is a summary disclosure of the audit results rather than the full 10-K annual report itself. In the context of Korean regulatory filings (DART), this is a standard 'Audit Report Submission' filing, which falls under the 'Audit Report / Information' category. FY 2025
2026-03-19 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Tego Science Inc. for the fiscal year ending December 31, 2025. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is a comprehensive financial document, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR) as it contains the audit opinion and the audited financial statements. FY 2025
2026-03-19 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date'. It explains the company's inability to avoid the concentrated date due to audit and logistical constraints. As this is a specific regulatory disclosure regarding meeting logistics and compliance with corporate governance reporting requirements, and does not fit into the specific categories for AGM materials, proxy statements, or voting results, it is best classified as a general regulatory filing.
2026-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.